2022
Oridonin ameliorates acetaminophen‐induced acute liver injury through ATF4/PGC‐1α pathway
Yu D, Li J, Wang Y, Guo D, Zhang X, Chen M, Zhou Z. Oridonin ameliorates acetaminophen‐induced acute liver injury through ATF4/PGC‐1α pathway. Drug Development Research 2022, 84: 211-225. PMID: 36567664, DOI: 10.1002/ddr.22024.Peer-Reviewed Original ResearchConceptsAcute liver injuryPGC-1α pathwayLiver injuryCytochrome P450 2E1 (CYP2E1) levelsEndoplasmic reticulum stress activationOxidative stressP450 2E1 levelsImproved liver functionPotential therapeutic effectsPGC-1α levelsHepatocyte cell deathUnclear molecular mechanismsLiver functionProinflammatory cytokinesHepatic toxicityHepatoprotective effectTherapeutic effectAPAP metabolismATF4 knockdownNecrotic areasWestern blotAPAPMetabolic activationMitochondrial dysfunctionProtein levels
2011
Hepatic Safety and Lack of Antiretroviral Interactions With Buprenorphine/Naloxone in HIV-Infected Opioid-Dependent Patients
Vergara-Rodriguez P, Tozzi MJ, Botsko M, Nandi V, Altice F, Egan JE, O'Connor PG, Sullivan LE, Fiellin DA. Hepatic Safety and Lack of Antiretroviral Interactions With Buprenorphine/Naloxone in HIV-Infected Opioid-Dependent Patients. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: s62-s67. PMID: 21317596, DOI: 10.1097/qai.0b013e31820a820f.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxoneOpioid-dependent patientsMedian aspartate aminotransferasePharmacodynamic interactionsAspartate aminotransferaseBup/ALT valuesAlanine aminotransferaseBUP/NXOpioid-dependent HIVProspective cohort studyHepatic safetyHepatitis CCohort studyHepatic toxicityHIVPatientsAtazanavirNaloxonePrior reportsExposure measuresSignificant decreaseAminotransferaseSignificant changesTreatment
2006
Abrogation of skin disease in LUPUS‐prone MRL/FASlpr mice by means of a novel tylophorine analog
Choi J, Gao W, Odegard J, Shiah H, Kashgarian M, McNiff JM, Baker DC, Cheng Y, Craft J. Abrogation of skin disease in LUPUS‐prone MRL/FASlpr mice by means of a novel tylophorine analog. Arthritis & Rheumatism 2006, 54: 3277-3283. PMID: 17009262, DOI: 10.1002/art.22119.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusEnd-organ diseaseInflammatory skin diseaseMRL/Skin diseasesMRL/Faslpr miceFemale MRL/NF-kappaB inhibitorFlow cytometric analysisFaslpr miceAutoantibody titersIgG levelsLupus erythematosusLymph nodesRenal diseaseVehicle treatmentKidney diseaseHepatic toxicityTotal IgMTylophorine analogsAntichromatin autoantibodiesTherapeutic effectHistopathologic analysisMurine modelSignificant abrogation
2005
Nonsteroidal Anti-Inflammatory Drugs and Hepatic Toxicity: A Systematic Review of Randomized Controlled Trials in Arthritis Patients
Rostom A, Goldkind L, Laine L. Nonsteroidal Anti-Inflammatory Drugs and Hepatic Toxicity: A Systematic Review of Randomized Controlled Trials in Arthritis Patients. Clinical Gastroenterology And Hepatology 2005, 3: 489-498. PMID: 15880319, DOI: 10.1016/s1542-3565(04)00777-3.Peer-Reviewed Original ResearchConceptsLiver-related deathLiver-related hospitalizationsSerious adverse eventsAnti-inflammatory drugsAminotransferase elevationAdverse eventsSide effectsNonsteroidal anti-inflammatory drugsTrials of diclofenacHepatic side effectsProportion of patientsClinical side effectsRandomized Controlled TrialsBibliographic databases MEDLINEHigh rateArthritis patientsControlled TrialsRheumatoid arthritisHepatic toxicityInclusion criteriaDatabases MEDLINENSAIDsDrug AdministrationSystematic reviewToxicity outcomes
2003
Use of the Peroxisome Proliferator-Activated Receptor (PPAR) γ Ligand Troglitazone as Treatment for Refractory Breast Cancer: A Phase II Study
Burstein HJ, Demetri GD, Mueller E, Sarraf P, Spiegelman BM, Winer EP. Use of the Peroxisome Proliferator-Activated Receptor (PPAR) γ Ligand Troglitazone as Treatment for Refractory Breast Cancer: A Phase II Study. Breast Cancer Research And Treatment 2003, 79: 391-397. PMID: 12846423, DOI: 10.1023/a:1024038127156.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerSerum tumor markersBreast cancerTumor markersTumor differentiationDisease progressionAdvanced breast cancer refractoryElevated serum tumor markersRefractory metastatic breast cancerPeroxisome proliferator-activated receptor γBreast cancer refractoryRefractory breast cancerPhase II studyPercentage of patientsProliferator-activated receptor γDifferent patient populationsCancer refractoryChemotherapy regimenII studyObjective responseSystemic therapyPO QDHormonal regimensHepatic toxicityPatient population
1999
Hepatic Toxicity and Persistence of ser/thr Protein Phosphatase Inhibition by Microcystin in the Little Skate Raja erinacea
Runnegar M, Seward D, Ballatori N, Crawford J, Boyer J. Hepatic Toxicity and Persistence of ser/thr Protein Phosphatase Inhibition by Microcystin in the Little Skate Raja erinacea. Toxicology And Applied Pharmacology 1999, 161: 40-49. PMID: 10558922, DOI: 10.1006/taap.1999.8783.Peer-Reviewed Original ResearchConceptsDose-dependent inhibitionSkate hepatocytesUptake of microcystinNear complete inhibitionPP activityInflammatory changesHepatic toxicityHepatocyte necrosisHistological changesAccompanying inhibitionHepatic lesionsBile acidsHigh dosesOnly organSignificant inhibitionSkate Raja erinaceaLittle skate Raja erinaceaInhibitionLiverRectal gland
1998
Therapeutic Angiogenesis With Basic Fibroblast Growth Factor: Technique and Early Results
Sellke F, Laham R, Edelman E, Pearlman J, Simons M. Therapeutic Angiogenesis With Basic Fibroblast Growth Factor: Technique and Early Results. The Annals Of Thoracic Surgery 1998, 65: 1540-1544. PMID: 9647055, DOI: 10.1016/s0003-4975(98)00340-3.Peer-Reviewed Original ResearchMeSH KeywordsAgedAlginatesAngina PectorisCollateral CirculationCoronary Artery BypassCoronary Artery DiseaseCoronary CirculationCoronary VesselsCreatinineDelayed-Action PreparationsDrug CarriersFeasibility StudiesFemaleFibroblast Growth Factor 2Follow-Up StudiesGlucuronic AcidHeparinHexuronic AcidsHumansMaleMiddle AgedMyocardial ContractionMyocardial InfarctionNeovascularization, PhysiologicPericardiumSafetyStroke VolumeSurvival RateConceptsBasic fibroblast growth factorCoronary artery bypassFibroblast growth factorArtery bypassGrowth factorTherapeutic angiogenesisConventional coronary artery bypassBasic fibroblast growth factor (bFGF) administrationSlow-release devicesStress perfusion scansPerioperative myocardial infarctionSerum creatinine levelsDifficult clinical problemFixed perfusion defectsLong-term resultsMyocardial contractile functionGrowth factor administrationOperative mortalityPatent arteriesMyocardial revascularizationCreatinine levelsEjection fractionClinical efficacyHepatic toxicityPerfusion scan
1978
Metabolism affects the hepatic toxicity of chlorprohazine (CPZ) in the isolated perfused rat liver (IPRL)
Tavoloni N, Nemchausky B, Reed J, Boyer J. Metabolism affects the hepatic toxicity of chlorprohazine (CPZ) in the isolated perfused rat liver (IPRL). Gastroenterology 1978, 75: 990. DOI: 10.1016/0016-5085(78)90661-3.Peer-Reviewed Original ResearchHepatic toxicityRat liver
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply